Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study

Journal of Alzheimer's Disease

Volumn 52, Issue 4, 2016, Pages 1321-1333

  Müller, Mareike ^a,b   Kuiperij, H Bea ^a,b   Versleijen, Alexandra A M ^b   Chiasserini, Davide ^c   Farotti, Lucia ^c   Baschieri, Francesca ^c   Parnetti, Lucilla ^c   Struyfs, Hanne ^d   De Roeck, Naomi ^d   Luyckx, Jill ^d   Engelborghs, Sebastiaan ^d,e   Claassen, Jurgen A ^a   Verbeek, Marcel M ^a,b  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e Hospital Network Antwerp ZNA Middelheim and Hoge Beuken   (Belgium)

Author keywords

Alzheimer's disease; cerebrospinal fluid; frontotemporal dementia; Lewy body disease; microRNAs; mild cognitive impairment

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 125B; MICRORNA 146A; MICRORNA 16; MICRORNA 24; MICRORNA 29A; SMALL NUCLEAR RNA; MIRN125 MICRORNA, HUMAN; MIRN146 MICRORNA, HUMAN; MIRN29 MICRORNA, HUMAN;

AGED; ARTICLE; BLOOD CELL COUNT; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VALIDATION STUDY; ALZHEIMER DISEASE; CASE CONTROL STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE COURSE; MIDDLE AGED; MULTICENTER STUDY;

AGED; ALZHEIMER DISEASE; BIOMARKERS; CASE-CONTROL STUDIES; COGNITIVE DYSFUNCTION; DEMENTIA; DISEASE PROGRESSION; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; LEWY BODY DISEASE; MALE; MICRORNAS; MIDDLE AGED;

EID: 84974530708     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160038     Document Type: Article

References (45)

1. Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101, 2087-2092.
2. El-Hefnawy T, Raja S, Kelly L, Bigbee WL, Kirkwood JM, Luketich JD, Godfrey TE (2004) Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem 50, 564-573.
3. Ge Q, Zhou Y, Lu J, Bai Y, Xie X, Lu Z (2014) miRNA in plasma exosome is stable under different storage conditions. Molecules 19, 1568-1575.
4. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39, 7223-7233.
5. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56, 1733-1741.
6. Leidinger P, Keller A, Borries A, Reichrath J, Rass K, Jager SU, Lenhof HP, Meese E (2010) High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 10, 262.
7. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG (2009) MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 69, 5776-5783.
8. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, Adamietz BR, Wenkel E, Rauh C, Beckmann MW, Fasching PA (2012) Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 7, e29770.
9. Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zollner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117, 3140-3146.
10. Delay C, Mandemakers W, Hebert SS (2012) MicroRNAs in Alzheimer's disease. Neurobiol Dis 46, 285-290.
11. Lukiw WJ, Zhao Y, Cui JG (2008) An NF-kappaBsensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 283, 31315-31322.
12. Hébert SS, Horré K, Nicoläi L, Papadopoulou AS, MandemakersW, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B (2008) Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/-secretase expression. Proc Natl Acad Sci U S A 105, 6415-6420.
13. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT (2008) The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28, 1213-1223.
14. Sala Frigerio C, Lau P, Salta E, Tournoy J, Bossers K, Vandenberghe R, Wallin A, BjerkeM, ZetterbergH, BlennowK, De Strooper B (2013) Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology 81, 2103-2106.
15. Müller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM (2014) MicroRNAs in Alzheimer's disease: Differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 35, 152-158.
16. Müller M, Jakel L, Bruinsma IB, Claassen JA, Kuiperij HB, Verbeek MM (2015) MicroRNA-29a is a candidate biomarker for alzheimer's disease in cell-free cerebrospinal fluid. Mol Neurobiol, doi: 10. 1007/s12035-015-9156-8
17. Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H, Miyazawa T (2014) MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J Alzheimers Dis 39, 253-259.
18. Alexandrov PN, Dua P, Hill JM, Bhattacharjee S, Zhao Y, Lukiw WJ (2012) microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol 3, 365-373.
19. Li J, Liu Y, Kim T, Min R, Zhang Z (2010) Gene expression variability within and between human populations and implications toward disease susceptibility. PLoS Comput Biol 6, pii: e1000910.
20. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA (2008) Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14, 27-41.
21. Hebert SS, Wang WX, Zhu Q, Nelson PT (2013) A study of small RNAs from cerebral neocortex of pathologyverified Alzheimer's disease, dementia with Lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis 35, 335-348.
22. Arrant AE, Roberson ED (2014) MicroRNA-124 modulates social behavior in frontotemporal dementia. Nat Med 20, 1381-1383.
23. Zhang Z, Almeida S, Lu Y, Nishimura AL, Peng L, Sun D, Wu B, Karydas AM, Tartaglia MC, Fong JC, Miller BL, Farese RV Jr, Moore MJ, Shaw CE, Gao FB (2013) Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations. PLoS One 8, e76055.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
25. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
26. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47, 1113-1124.
27. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration:Aconsensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
28. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, PhelpsCH(2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
29. Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P (2012) Performance of abeta1-40, abeta1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 29, 229-238.
30. Le Bastard N, De Deyn PP, Engelborghs S (2015) Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem 61, 734-743.
31. Sheinerman KS, Tsivinsky VG, Abdullah L, Crawford F, Umansky SR (2013) Plasma microRNA biomarkers for detection of mild cognitive impairment: Biomarker validation study. Aging (Albany NY) 5, 925-938.
32. Sheinerman KS, Tsivinsky VG, Crawford F, Mullan MJ, Abdullah L, Umansky SR (2012) Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany NY) 4, 590-605.
33. Xie B, Zhou H, Zhang R, Song M, Yu L, Wang L, Liu Z, Zhang Q, Cui D, Wang X, Xu S (2015) Serum miR-206 and miR-132 as potential circulating biomarkers for mild cognitive impairment. J Alzheimers Dis 45, 721-731.
34. Zhu Y, Li C, Sun A, Wang Y, Zhou S (2015) Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer's disease. Exp Ther Med 9, 1013-1017.
35. Liu CG, Song J, Zhang YQ, Wang PC (2014) MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease. Mol Med Rep 10, 2395-2400.
36. Jiao J, Herl LD, Farese RV, Gao FB (2010) MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. PLoS One 5, e10551.
37. Gascon E, Lynch K, Ruan H, Almeida S, Verheyden JM, Seeley WW, Dickson DW, Petrucelli L, Sun D, Jiao J, Zhou H, Jakovcevski M, Akbarian S, Yao WD, Gao FB (2014) Alterations in microRNA-124 and AMPA receptors contribute to social behavioral deficits in frontotemporal dementia. Nat Med 20, 1444-1451.
38. Fleige S, PfafflMW(2006) RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 27, 126-139.
39. Peiro-Chova L, Pena-Chilet M, Lopez-Guerrero JA, Garcia-Gimenez JL, Alonso-Yuste E, Burgues O, Lluch A, Ferrer-Lozano J, Ribas G (2013) High stability of microRNAs in tissue samples of compromised quality. Virchows Arch 463, 765-774.
40. Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Decard BF, Thum T, Gold R (2012) Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study. Neurology 79, 2166-2170.
41. Qureshi R, Sacan A (2013) A novel method for the normalization of microRNA RT-PCR data. BMC Med Genomics 6 (Suppl 1), S14.
42. Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A (2015) Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. Clin Chim Acta 449, 9-15.
43. Sethi P, Lukiw WJ (2009) Micro-RNA abundance and stability in human brain: Specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci Lett 459, 100-104.
44. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, Stahler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A (2013) A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol 14, R78.
45. Shi R, Wang PY, Li XY, Chen JX, Li Y, Zhang XZ, Zhang CG, Jiang T, Li WB, Ding W, Cheng SJ (2015) Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget 6, 26971-26981.